David Hutton

According to the company, LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.

Delaying the disease can also delay any onset of vision problems, including diabetic retinopathy and diabetic macular edema.

According to the company, ROP Check builds upon its pediatric retina screening portfolio, adding digital management (schedule, document, bill, and transfer) for treating patients with retinopathy of prematurity.

RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions.

A previously uncharacterized area of the protein known as RPE65 spontaneously turns spiral-shaped when it encounters intracellular membranes, or thin structures that surround different parts of a cell.

Genentech announced this week that faricimab-svoa (Vabysmo) achieved its primary endpoint of non-inferiority compared to aflibercept in RVO in the BALATON and COMINO clinical trials.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

The company noted that the pediatric exclusivity determination is based on data from two Phase 3 trials – BUTTERFLEYE and FIREFLEYE.

Carl Danzig, MD, points out that the sooner patients can be diagnosed, the sooner ophthalmologists can treat them and preserve their vision.

MCO-010, an ambient-light activatable multi-characteristic opsin optogenetic monotherapy for vision restoration in blind patients, received fast track designation from the FDA.

According to data released at the American Academy of Ophthalmology's 2022 annual meeting, a large number of wet AMD patients do not return for treatment.

Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).

Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.

LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.

The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois, from September 30 to October 3, featuring Subspecialty Days and a virtual component.

Oral APX3330 was found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 prior trials of APX3330.

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.

According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.

According to data from Prevent Blindness, there were more than 26,000 sports-related eye injuries treated in the United States last year.

Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that shows promise for treating the dry form of age-related macular degeneration (AMD).

Gene therapy has partly restored the function of the retina’s cone receptors in two children who were born completely colorblind, reports a new study led by UCL researchers.

According to the company, results showed increased effects over time with pegcetacoplan, with treatment effect accelerated between months 18 and 24.

The deal will expand Alcon's footprint in the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to existing commercial efforts.

APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.

Researchers at the Medical University of Vienna are focusing on how the retina can be used as a prognostic marker. Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and the likelihood of disability.

With the support of Harrington Discovery Institute at University Hospitals, an ophthalmic therapeutic dubbed KIO-301, initially developed by Richard Kramer, PhD, at the University of California, Berkeley (UCB), has successfully been granted approval to start a Phase 1b, first-in-human clinical trial.